
Accepted Manuscript

Modified high-dose melphalan and autologous stem cell transplantation for AL amyloidosis: Experience in 334 patients

Vina P. Nguyen, Heather Landau, Karen Quillen, Dina Brauneis, Anthony C. Shelton, Lisa Mendelson, Hafsa Rahman, J. Mark Sloan, Shayna Sarosiek, Vaishali Sanchorawala

PII:S1083-8791(18)30330-6DOI:10.1016/j.bbmt.2018.06.018Reference:YBBMT 55164



To appear in: Seminars in Spine SurgerySeminars in Arthritis & Rheumatism

Received date:8 May 2018Accepted date:11 June 2018

Please cite this article as: Vina P. Nguyen, Heather Landau, Karen Quillen, Dina Brauneis, Anthony C. Shelton, Lisa Mendelson, Hafsa Rahman, J. Mark Sloan, Shayna Sarosiek, Vaishali Sanchorawala, Modified high-dose melphalan and autologous stem cell transplantation for AL amyloidosis: Experience in 334 patients, *The End-to-end Journal* (2018), doi: 10.1016/j.bbmt.2018.06.018

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights

- Risk adapted modified high dose melphalan/stem cell transplantation is effective in AL amyloidosis.
- Median OS and EFS are 6.1 and 4.3 years, respectively, in 334 AL amyloidosis patients treated with mHDM/SCT.
- Overall hematologic CR+VGPR rate is 53%, and TRM is 10% with mHDM/SCT in AL.
- Median OS is 13.4 years for those achieving a hematologic CR after mHDM/SCT in AL.

A CHIER MAN

Download English Version:

https://daneshyari.com/en/article/10157452

Download Persian Version:

https://daneshyari.com/article/10157452

Daneshyari.com